- ABOUT RHYTHM
- CAREERS
- CONTACT
- NEWS & RESOURCES
- PRESS RELEASES
- FDA Office of Orphan Products Development Awards Rhythm $1 Million Grant to Support Phase 2 Study of Setmelanotide in Prader-Willi Syndrome
- FierceBiotech Names Rhythm as a “Fierce 15” Biotechnology Company of 2016
- Ipsen Grants Rhythm Exclusive Worldwide License for Two Programs in the Field of Metabolic Disorders
- Rhythm and Camurus Announce License Agreement for Extended Release FluidCrystal Setmelanotide
- Rhythm and Camurus Announce Positive Initial Data for Extended-Release Delivery of Setmelanotide for the Treatment of Rare Genetic Disorders of Obesity
- Rhythm Announces $21 Million Series A
- Rhythm Announces Completion of $41 Million Mezzanine Financing
- Rhythm Announces New England Journal of Medicine Publication of Setmelanotide Phase 2 Data for Treatment of POMC Deficiency Obesity
- Rhythm Announces “The Genetic Obesity Project” to Expand Understanding of Rare Genetic Disorders of Obesity
- Rhythm Appoints David Meeker, MD, and David McGirr to Board of Directors
- Rhythm Appoints Fred T. Fiedorek, M.D., Chief Medical Officer
- Rhythm Appoints Head of Sanofi Genzyme, Dr. David Meeker, as Chairman of Board of Directors
- Rhythm Closes $40 Million Series A Financing
- Rhythm Expands Executive Leadership Team
- Rhythm Expands Phase 2 Clinical Trials of Setmelanotide to the Treatment of Bardet-Biedl Syndrome Obesity
- Rhythm Expands Scientific Advisory Board for Clinical Programs in Metabolic Diseases
- Rhythm Expands Series B Financing to $33 Million; Adds Pfizer Ventures as an Investor
- Rhythm Initiates Clinical Trial of RM-493 for Obesity Caused by Genetic Variant
- Rhythm Initiates Phase 2 Clinical Trial of RM-493 for Obesity
- Rhythm Initiates Two Phase 2 Clinical Trials of Setmelanotide (RM-493) in Rare Genetic Disorders of Obesity Caused by MC4 Pathway Deficiencies
- Rhythm Names Keith M. Gottesdiener Chief Executive Officer
- Rhythm Names Lex Van der Ploeg Chief Scientific Officer
- Rhythm Presents Cardiovascular Safety Data from Phase 1b/2a Clinical Trials of Setmelanotide in Obesity
- Rhythm Presents Clinical Data that RM-493 Increases Energy Expenditure in Obesity Study
- Rhythm Presents Positive Data from Phase 1b Study of Setmelanotide for the Treatment of Genetic Obesity
- Rhythm Presents Positive Initial Data for Setmelanotide in LepR Deficiency Obesity
- Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics
- Rhythm Receives Expanded FDA Breakthrough Therapy Designation for Setmelanotide for Rare Genetic Disorders of Obesity
- Rhythm Receives FDA Breakthrough Therapy Designation for Setmelanotide for Treatment of POMC Deficiency Obesity
- Rhythm Receives Orphan Drug Designation for Setmelanotide for the Treatment of Prader-Willi Syndrome
- Rhythm Starts Phase 3 Clinical Trial of Setmelanotide for Rare Genetic Disorder of Obesity
- Rhythm Subsidiary Raises $40 Million in Oversubscribed Financing
- RHYTHM IN THE NEWS
- PRESS RELEASES
- PIPELINE
- PRIVACY POLICY
- Sitemap
- TERMS OF USE
